June 22, 2020
MTF Biologics, a global nonprofit organization that saves and heals lives through advancing tissue and organ donation, transplantation, and research, today announced that new positive coverage decisions by Aetna, Centene Corporation, WellCare and Tufts Health Plan will provide greater access to its human placental and dermal allografts, AmnioBand® and AlloPatch®, for the treatment of diabetic foot ulcers (DFUs).
In revising their coverage, Aetna, one of the largest commercial health insurance plans in the nation with over 22 million members, as well as Centene, WellCare, and Tufts Health Plan, join the likes of Anthem®, Cigna®, regional health insurance plans including all Blue Cross® and Blue Shield® plans, Medicare, and a number of state Medicaid programs in providing access to these tissue forms to over 240 million Americans.
This sweeping expansion of coverage means that even more Americans who are suffering with complex and chronic wounds, such as DFUs, will have access to these safe, clinically proven and cost-effective human allograft treatment options. This wider coverage is especially critical today as Americans are facing more health and economic challenges due to the COVID-19 pandemic.
Published studies have shown that these high-quality tissue forms have some of the lowest cost to closure rates and better outcomes when compared to other tissues on the market — aligning with our nation’s move from a fee-for-service to a value-based health care delivery and reimbursement model.
“Our patients are our first priority at MTF Biologics, and we are determined that Americans who are suffering with complex and chronic wounds have access to our allograft solutions to help them recover and heal,” said Joe Yaccarino, President and CEO of MTF Biologics. “Today 34 million Americans suffer from diabetes and one in four of them will likely develop a diabetic foot ulcer. In this time of health and economic uncertainty, the last thing they should be concerned about is access to treatment. This recent expansion of coverage furthers our mission of honoring the gift of donation by ensuring that our vital wound care allografts are available to Americans who need them.”
The AmnioBand innovative family of placental allografts and the AlloPatch dermal based technologies can be used to treat a variety of complex and chronic wounds, such as DFUs, venous leg ulcers and decubitus ulcers. The AmnioBand placental family of solutions are minimally processed human placental allografts that retain the structural properties of an extracellular matrix, serving as a premier wound covering for complex and chronic wounds. AlloPatch Pliable is a pliable human reticular dermal matrix, providing a framework for cellular repopulation and vascularization at the surgical site.
“MTF Biologics is committed to providing innovative, effective wound care tissue forms to the patients who need them,” said Kim Rounds, MTF Biologics Vice President of Wound Care. “Our team of clinicians and scientists have worked for years to develop allograft solutions that save and heal lives and to publish the robust clinical evidence needed to gain broad insurance coverage. We are proud, that with these recent coverage decisions, now over 240 million Americans have access to our life-changing human allografts.”